MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Myriad Genetics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

8.8

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.59

Max

8.91

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-20M

-43M

Pardavimai

-2.7M

211M

Pelnas, tenkantis vienai akcijai

0.03

Pelno marža

-20.18

Darbuotojai

2,700

EBITDA

19M

-2.2M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+75.56% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-227M

911M

Ankstesnė atidarymo kaina

8.8

Ankstesnė uždarymo kaina

8.8

Naujienos nuotaikos

By Acuity

50%

50%

163 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Myriad Genetics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-31 22:45; UTC

Svarbiausios naujienos

Intel's New CEO Plots Turnaround; 'We Need to Improve'

2025-03-31 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise After Monday's Selloff -- Market Talk

2025-03-31 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Tower Shares Ease After Bain Capital Exit -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-03-31 22:33; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

2025-03-31 22:28; UTC

Uždarbis

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke Swings to Loss for 2024 >000002.SZ

2025-03-31 21:47; UTC

Svarbiausios naujienos

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

2025-03-31 21:44; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

2025-03-31 21:21; UTC

Rinkos pokalbiai

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

2025-03-31 21:18; UTC

Svarbiausios naujienos

Copper Is 2025's Hottest Commodity -- Update

2025-03-31 21:09; UTC

Svarbiausios naujienos

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

2025-03-31 21:02; UTC

Uždarbis

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

2025-03-31 21:01; UTC

Uždarbis

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

2025-03-31 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-03-31 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-03-31 20:37; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

2025-03-31 20:17; UTC

Svarbiausios naujienos

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

2025-03-31 20:13; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

2025-03-31 20:03; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

2025-03-31 19:09; UTC

Rinkos pokalbiai

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

2025-03-31 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains With Help From Weather -- Market Talk

2025-03-31 18:54; UTC

Rinkos pokalbiai

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

2025-03-31 18:40; UTC

Rinkos pokalbiai

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

2025-03-31 18:34; UTC

Rinkos pokalbiai

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

2025-03-31 18:28; UTC

Rinkos pokalbiai

Gold Climbs to Close Out Quarter -- Market Talk

2025-03-31 18:03; UTC

Svarbiausios naujienos

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Akcijų palyginimas

Kainos pokytis

Myriad Genetics Inc Prognozė

Kainos tikslas

By TipRanks

75.56% į viršų

12 mėnesių prognozė

Vidutinis 15.59 USD  75.56%

Aukščiausias 22 USD

Žemiausias 11 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Myriad Genetics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

12 ratings

5

Pirkti

4

Laikyti

3

Parduoti

Techninis įvertinimas

By Trading Central

8.7 / 10Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

163 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.